Eton Pharmaceutical | 4: Statement of changes in beneficial ownership of securities-10% Owner Opaleye Management Inc.
Eton Pharmaceutical | 3: Initial statement of beneficial ownership of securities-10% Owner Opaleye Management Inc.
Eton Pharmaceutical | 10-Q: Q2 2024 Earnings Report
Eton Pharmaceutical | 8-K: Current report
Eton Pharmaceutical | 8-K/A: Current report (Amendment)
Eton Pharmaceutical | 8-K: Current report
Eton Pharmaceutical | 8-K: Current report
Eton Pharmaceutical | 8-K: Current report
Eton Pharmaceutical | 10-Q: Q1 2024 Earnings Report
Eton Pharmaceutical | 8-K: Current report
Eton Pharmaceutical | 8-K: Current report
Eton Pharmaceutical | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Harrow, Inc.(0.0%)
Eton Pharmaceutical | DEF 14A: Definitive information statements
Eton Pharmaceutical | 8-K: Current report
Eton Pharmaceutical | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Eton Pharmaceutical | 10-K/A: Annual report (Amendment)
Eton Pharmaceutical | 8-K: Current report
Eton Pharmaceutical | 10-K: FY2023 Annual Report
Eton Pharmaceutical | 8-K: Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
Eton Pharmaceutical | 8-K: Current report
No Data
No Data